%0 Journal Article
%A Moreso, Francesc
%A Crespo, Marta
%A Ruiz, Juan C
%A Torres, Armando
%A Gutierrez-Dalmau, Alex
%A Osuna, Antonio
%A Perelló, Manel
%A Pascual, Julio
%A Torres, Irina B
%A Redondo-Pachón, Dolores
%A Rodrigo, Emilio
%A Lopez-Hoyos, Marcos
%A Seron, Daniel
%T Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
%D 2017
%U http://hdl.handle.net/10668/11613
%X There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)
%K clinical research/practice
%K clinical trial
%K kidney (allograft) function/dysfunction
%K kidney transplantation/nephrology
%K pathology/histopathology
%K rejection: antibody-mediated (ABMR)
%~